Evidence map›Paper›PMID 42639086›Full record

ArticleACS nano medicine2026

João M J M Ravasco, Jhenifer Oliveira, João Conniot, Bárbara B Mendes, Catarina Leal, Susete N Fernandes, Carlos A M Afonso, João Conde

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS nano medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

João M J M RavascoNOVA Medical School|Faculdade de Ciências Médicas, NMS|FCM, Universidade NOVA de Lisboa, 1169-056 Lisbon, Portugal.
Jhenifer OliveiraNOVA Medical School|Faculdade de Ciências Médicas, NMS|FCM, Universidade NOVA de Lisboa, 1169-056 Lisbon, Portugal.
João ConniotNOVA Medical School|Faculdade de Ciências Médicas, NMS|FCM, Universidade NOVA de Lisboa, 1169-056 Lisbon, Portugal.
Bárbara B MendesNOVA Medical School|Faculdade de Ciências Médicas, NMS|FCM, Universidade NOVA de Lisboa, 1169-056 Lisbon, Portugal.ORCID https://orcid.org/0000-0001-8630-1119
Catarina Leali3N/CENIMAT, Department of Materials Science, NOVA School of Science and Technology, Universidade NOVA de Lisboa, Campus de Caparica, 2829-516 Caparica, Portugal.
Susete N Fernandesi3N/CENIMAT, Department of Materials Science, NOVA School of Science and Technology, Universidade NOVA de Lisboa, Campus de Caparica, 2829-516 Caparica, Portugal.ORCID https://orcid.org/0000-0002-7871-6717
Carlos A M AfonsoInstituto de Investigação do Medicamento (iMed), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal.ORCID https://orcid.org/0000-0002-7284-5948
João CondeNOVA Medical School|Faculdade de Ciências Médicas, NMS|FCM, Universidade NOVA de Lisboa, 1169-056 Lisbon, Portugal.ORCID https://orcid.org/0000-0001-8422-6792

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To address the critical challenge of high-lethality pancreatic ductal adenocarcinoma and poor response to conventional chemotherapies, this study introduces a self-immolative micelle encapsulating paclitaxel (PTX) or gemcitabine (GEM), two frontline chemotherapeutic agents. These chemotherapeutic agents present a 2.3-fold reduction for GEM and a 61.7-fold reduction for PTX in IC

Indexed as

biomarkergemcitabinehydrogellocal deliverymicellespaclitaxelpancreatic ductal adenocarcinomatherapeutic target

Identifiers

PMID42639086
PMCPMC13501496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.